YK-11

Overview

YK-11 is a synthetic compound that occupies an unusual position in the research chemical landscape. First described by Japanese researcher Yuichiro Kanno in 2011, YK-11 was initially characterized as a selective androgen receptor modulator (SARM) with an additional, distinctive property: the ability to inhibit myostatin through a follistatin-dependent mechanism. This dual activity sets YK-11 apart from other SARMs and has generated both scientific curiosity and considerable speculation about its potential as an anabolic agent.

Structurally, YK-11 is a steroidal compound derived from dihydrotestosterone (DHT), which distinguishes it from the non-steroidal SARMs like RAD-140 and LGD-4033. Its steroidal backbone raises questions about whether the “SARM” designation is fully appropriate, as the compound may share more pharmacological characteristics with traditional anabolic steroids than its marketing would suggest. The limited research base, consisting primarily of in vitro studies with no published in vivo animal data or human clinical trials, makes definitive pharmacological classification difficult.

Mechanism of Action

YK-11’s mechanism of action has been elucidated primarily through cell culture experiments. In C2C12 myoblast cells, YK-11 activates the androgen receptor and promotes myogenic differentiation, consistent with SARM-like activity. However, the compound’s most distinctive effect is the induction of follistatin expression. Follistatin is a glycoprotein that binds and neutralizes myostatin (also called growth differentiation factor 8, or GDF-8), a member of the TGF-beta superfamily that serves as a potent negative regulator of skeletal muscle mass.

Myostatin acts as a brake on muscle growth. Animals with naturally occurring myostatin gene mutations or deletions display dramatic muscular hypertrophy, as demonstrated by Belgian Blue cattle and myostatin-knockout mice. By increasing follistatin levels, YK-11 could theoretically release this brake, allowing for enhanced muscle growth beyond what androgen receptor activation alone would produce.

The Kanno laboratory demonstrated that YK-11 increased follistatin mRNA expression in C2C12 cells to levels significantly above control conditions and above those produced by DHT at equivalent concentrations. This follistatin induction appeared to be partially independent of androgen receptor activation, suggesting that YK-11 may engage additional signaling pathways. The compound also stimulated the expression of osteoblast differentiation markers, including alkaline phosphatase and osteoprotegerin, in bone cells, suggesting potential anabolic effects on bone tissue.

One important caveat: the PKC (protein kinase C) signaling pathway has been implicated in YK-11’s follistatin induction, but the precise molecular targets and the degree to which these in vitro findings translate to whole-organism physiology remain entirely unknown. The absence of in vivo data represents a fundamental gap in the understanding of this compound.

Research Summary

The published scientific literature on YK-11 is remarkably thin compared to other commonly discussed SARMs. The total body of peer-reviewed research consists of a small number of publications from the Kanno laboratory, all based on in vitro experiments using cultured cell lines. No preclinical animal pharmacology studies, pharmacokinetic studies, toxicology studies, or human clinical trials have been published as of the current date.

The original 2011 publication showed that YK-11 partially activated the androgen receptor in a reporter gene assay, producing approximately 60% of the maximal activation achieved by DHT. At the same time, it induced follistatin expression to a greater degree than DHT. Follow-up publications examined the compound’s effects on osteoblast differentiation and confirmed the involvement of follistatin and PKC signaling pathways.

The absence of in vivo data means that fundamental pharmacological questions remain unanswered. Oral bioavailability, metabolic stability, tissue distribution, half-life, and dose-response relationships in intact organisms are all unknown. Whether the myostatin-inhibiting effects observed in cell culture produce meaningful muscle growth in animals (let alone humans) has not been tested in any published study.

Anecdotal reports from the research community suggest that YK-11 produces noticeable increases in muscle hardness and strength at doses of 5 to 15 mg daily over four-to-eight-week periods. Users frequently describe effects that feel more potent than those of non-steroidal SARMs, which is consistent with the compound’s steroidal structure. However, these reports are subject to all the limitations of uncontrolled, self-reported data, including placebo effects, concurrent use of other compounds, and variable product purity.

Dosing in Published Research

YK-11 is a synthetic compound marketed as a selective androgen receptor modulator. It has not been studied in any published human clinical trial, so no controlled research has established a dose for it in people; the available data are limited to laboratory and cell studies. Specific YK-11 figures circulating in forums or vendor material are not derived from human research and are therefore not reported here.

Safety and Side Effects

The safety profile of YK-11 is essentially uncharacterized in any rigorous scientific sense. No toxicology studies have been published, and no regulatory agency has evaluated the compound for safety in any species. This represents a level of uncertainty that is unusual even among investigational research chemicals, most of which have at least basic preclinical toxicology data available.

Given its steroidal structure and DHT-derived backbone, several safety concerns can be inferred from pharmacological first principles. DHT-derived compounds are known to suppress endogenous testosterone production through HPG axis negative feedback, and user reports consistently describe testosterone suppression with YK-11 use. Androgenic side effects including hair loss, acne, and prostate stimulation are theoretically possible, though the degree of tissue selectivity (if any) has not been characterized in vivo.

Hepatotoxicity is a particular concern. YK-11 contains a methylated ester group at the C-17 position, a structural feature shared with many oral anabolic steroids associated with liver stress. User-reported bloodwork has shown elevations in liver transaminases (ALT and AST) during YK-11 use, sometimes to levels several times the upper limit of normal. Whether these elevations represent clinically significant liver damage or a transient, benign hepatocellular stress response cannot be determined from available data.

Lipid profile changes, including HDL suppression and LDL elevation, have been reported anecdotally. Effects on cardiovascular health, bone mineral density, reproductive function, and cancer risk are entirely unknown.

Current Research Status

YK-11 is an early-stage research compound with no clinical development program, no regulatory submissions, and no approved indications. It is prohibited by WADA in competitive sport. The compound’s unique mechanism combining AR agonism with myostatin inhibition makes it a scientifically interesting molecule, but the near-total absence of in vivo data places it among the least-characterized compounds commonly available in the research chemical market. Any research use must account for the substantial unknowns surrounding its pharmacology, metabolism, and toxicology.

Further reading: For research on two related selective androgen receptor modulators, see RAD-140 vs LGD-4033: Comparing Two Researched SARMs.

Frequently Asked Questions